Stocks Recap: Enduro Royalty Trust, Claude Resources Inc, Bulova Technologies Group, Sunesis Pharmaceuticals

Lakeway, TX -- (SBWIRE) -- 02/19/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Enduro Royalty Trust (NYSE:NDRO) went down 5.33% and closed at $15.81. The Company announced a cash distribution to the holders of its units of beneficial interest of $0.070519 per unit, payable on March 14, 2013, to unit holders of record on February 28, 2013. The distribution primarily represents oil production during the month of November 2012 and natural gas production during October 2012.

Is NDRO after A Solid Pop Up? Find Out Here

Claude Resources Inc. (USA) (NYSE:CGR) declined 5.47% and closed at $0.484. The Company has completed the shaft extension project at its 100% owned and operated Seabee Gold Operation in Saskatchewan, Canada. The project extended the shaft from 600 meters to 980 meters depth. During the 20 day shutdown the Company was able to maintain production that averaged over 700 tonnes per day throughput to the central milling facility.

Will CGR Continue To Trend Higher After The Recent Gain? Find Out Here

Bulova Technologies Group, Inc. (PINK:BLVT)closed at $0.0002. The Company reported the successful completion of it’s on time delivery for Non Standard Ammunition to the US Army for $568,054.50. This sale will be recorded on the Company’s 2nd quarter.The Company is currently responding to new pricing requests from the US Army for an additional seventeen Non Standard Ammunition items per the Blanket Purchase Agreement with the US Government which is active through January, 27 2016.

Is BLVT a Buy Opportunity After The Recent Slump? Find Out Here

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) went down 5.0% and closed at $5.51.So far this year, the stock is up over 31%. The 52-week range for the stock is $1.57 and $6.85.Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

Is SNSS Still a Buy After The Recent momentum? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.